Liquidia shares plunged nearly 50% after a US court ruled against the company in a patent dispute with United Therapeutics, raising concerns over Yutrepia’s commercial prospects.
Market Samachar is a news aggregator. This article was originally published by Markets-Economic Times. Tap the button above to read the full story on their site.